A multicenter observational study on the efficacy and tolerability of Privigen® (intravenous immunoglobulin preparation) - Interim analysis with focus on immune thrombocytopenia (ITP)

被引：0
|
作者：
Tschechne, B.
Otremba, B.
Lotichius, P. [1 ]
Pfruender, D. [1 ]
机构：
[1] CSL Behring, Hattersheim, Germany
来源：
ONKOLOGIE | 2011年 / 34卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：170 / 171
页数：2
相关论文
共 46 条
  • [21] TREATMENT OF ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) WITH ROMIPLOSTIM IN ROUTINE CLINICAL PRACTICE IN GERMANY-INTERIM RESULTS FROM AN OBSERVATIONAL STUDY (PLATEAU)
    Welslau, M.
    Reiser, M.
    Illmer, T.
    Josten, K.
    Dietzfelbinger, H.
    Seitz, A.
    HAEMATOLOGICA, 2014, 99 : 204 - 204
  • [22] Safety and efficacy of a 10% intravenous immunoglobulin preparation in patients with immune thrombocytopenic purpura: results of two international, multicenter studies
    Kovaleva, Lidia
    Apte, Shashikant
    Damodar, Sharat
    Ramanan, Vijay
    Loriya, Svetlana
    Navarro-Puerto, Jordi
    Khojasteh, Ali
    IMMUNOTHERAPY, 2016, 8 (12) : 1371 - 1381
  • [23] Tolerability of the intravenous immunoglobulin Octagam® 5% - Interim analysis of a non-interventional study after market return in Germany
    Schultz, C.
    Kremer, S.
    ONKOLOGIE, 2012, 35 : 61 - 61
  • [24] Influence of the treatment of immune thrombocytopenia (ITP) with Eltrombopag on the fatigue symptoms of ITP patients - Results of the third interim analysis of the German non-interventional study RISA
    Meyer, O.
    Stauch, M.
    Kaempfe, D.
    Schlag, R.
    Reiser, M.
    Stauch, T.
    von der Heyde, E.
    Josting, A.
    Plath, M.
    Ballerstaedt, N.
    Stark-Lorenzen, P.
    Scheibenbogen, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 179 - 179
  • [25] REDUCED HOSPITALIZATIONS AND BLEEDS IN ADULTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) RECEIVING ROMIPLOSTIM IN CLINICAL PRACTICE - INTERIM RESULTS FROM A LARGE, EUROPEAN, OBSERVATIONAL STUDY
    Steurer, M.
    Janssens, A.
    Selleslag, D.
    Wadenvik, H.
    Quittet, P.
    Kaiafa, G.
    Kozak, T.
    Papadaki, H.
    Viallard, J.
    Belton, L.
    Kreuzbauer, G.
    HAEMATOLOGICA, 2013, 98 : 194 - 195
  • [26] Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations
    Meyer, Oliver
    Schlag, Rudolf
    Stauch, Thomas
    Fleischmann, Bastian
    Reiser, Marcel
    Kaempfe, Dietrich
    Behlendorf, Timo
    Welslau, Manfred
    von der Heyde, Eyck
    Doerfel, Steffen
    Willy, Claudia
    Stauch, Martina
    BLOOD, 2022, 140 : 2683 - 2684
  • [27] Efficacy, Safety and Tolerability of E5501 (AKR501) In a 6-Month Extension Study In Subjects with Chronic Immune Thrombocytopenia (ITP)
    Bussel, James B.
    Zhang, Jenny
    Tang, Shande
    McIntosh, Joe
    Kuter, David J.
    BLOOD, 2010, 116 (21) : 1516 - 1516
  • [28] Interim Baseline Characteristics of Adult Patients with Immune Thrombocytopenia Enrolled in the Observational Multicenter Phase 4 Adopt Study to Evaluate the Use and Effectiveness of Avatrombopag
    Ghanima, Waleed
    McDonald, Vickie
    Putnik, Milica
    Jamieson, Brian
    Lethagen, Stefan Rune
    BLOOD, 2023, 142
  • [29] An Interim Analysis Of a Phase 2, Single-Arm Study Of Platelet Responses and Remission Rates In Patients With Immune Thrombocytopenia (ITP) Receiving Romiplostim
    Stasi, Roberto
    Newland, Adrian
    Godeau, Bertrand
    Priego, Victor
    Viallard, Jean-Francois
    Fernandez, Maria Fernanda Lopez
    Jia, Catherine
    Lopez, Angela
    BLOOD, 2013, 122 (21)
  • [30] Tolerability and efficacy of the intravenous immunoglobulins octagam® 5% and octagam® 10% in secondary immunodeficiencies - Interim analysis of a non-interventional study
    Tschechne, B.
    Jansen, M.
    Klein, I
    Lietz, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 297 - 297
12345